Special Issue "CAR-T Cell Therapy against Different Types of Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 June 2017)
Dr. Vita Golubovskaya
1. Research and Business Development, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
2. Department of Medicine, University of Oklahoma, Oklahoma City, OK 73126, USA
Website | E-Mail
Interests: Immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signaling
CAR-T (chimeric antigen receptor) cell therapy is a novel type of cellular immunotherapy that recently provided highly promising results in treating patients with hematological cancers and other types of cancer, such as glioblastoma. The chimeric antigen receptor construct involves a signaling peptide; antibody part (scFv, single chain variable fragment), which binds to tumor antigen; hinge; different co-activation domains and activation CD3 domains. Once CAR binds to the tumor antigen, a T cell expressing CAR initiates killing of tumor cells due to the turned-on signaling from co-and activation signals. There are many challenges for this novel therapy, such as increasing its safety, efficacy in solid cancers, and overcoming on-target-off-tumor activity. This Special Issue highlights novel approaches for CAR-T therapy, focuses on CAR-T therapy against different types of cancer, discusses challenges in manufacturing of CAR-T cells and presents clinical advances and summarized perspectives in this field.
Dr. Vita Golubovskaya
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.